Oncoplastic breast surgery encompasses a range of techniques used to provide equitable oncological outcomes compared with standard breast surgery while, simultaneously, prioritizing aesthetic outcomes. While the outcomes of oncoplastic breast surgery are promising, it can add an extra complexity to the treatment paradigm of breast cancer and impact on decision-making surrounding adjuvant therapies, like chemotherapy and radiotherapy. As such, early discussions at the multidisciplinary team meeting with surgeons, medical oncologists, and radiation oncologists present, should be encouraged to facilitate best patient care.
Background: The impact of near-total resection of IDH-mutated anaplastic glioma (IDHmutAG) is well-established but there remains uncertainty of benefit in tumours of the insular cortex where the extent of safe resection may be limited. This study aimed to assess tumour volume reduction in patients following IMRT and impact of residual post-surgical volume. Methods and materials: Patients with IDHmutAG involving insular cortex managed with IMRT from 2008 to 2019 had baseline patient, tumour and treatment factors recorded. Volumetric assessment of residual disease on MRI was performed at baseline, month+ 3 and month+ 12 post-IMRT. Potential prognostic factors were analysed for tumour reduction and relapse-free survival, and assessed by log-rank and Cox regression analyses. Results: Thirty two patients with IDHmutAG of the insular cortex were managed with median follow-up post-IMRT of 67.2 months. Pathology was anaplastic astrocytoma (AAmut) in 20, and anaplastic oligodendroglioma (AOD) in 12 patients. Median pre-IMRT volume on T1 and T2Flair was 24.3cm3 and 52.2cm3. Twenty-seven patients were alive with 5-year relapse-free survival of 80%. There was a median 67 and 64% reduction from baseline occurring at 3 months post-IMRT for T1 and T2Flair respectively; and subsequent median 78 and 73% at 12 months. At 12 months AOD patients had median 83% T1 volume reduction compared to 63% in AAmut (p < 0.01). There was no difference on T2Flair volume (p = 0.64). No other pathological factors influenced volume reduction at 12 months. No factors were associated with relapse-free survival including baseline T1 (p = 0.52) and T2Flair (p = 0.93) volume. Conclusion: IMRT provides large tumour volume reduction in IDHmutAG of the insular cortex. While maximal safe debulking remains standard of care when feasible, this patient cohort reported no significant negative impact of residual disease volume on relapse-free survival.
Background: In IDH-mutated anaplastic glioma (IDHmutAG) of the insular cortex there remains uncertainty of benefit with near-total resection compared to limited surgery with radiation therapy (IMRT). This study aimed to assess tumour volume reduction in patients following IMRT and impact of residual post-surgical volume. Methods and Materials:Patients with IDHmutAG involving insular cortex managed with IMRT from 2008-2019 had baseline patient, tumour and treatment factors recorded. Volumetric assessment of residual disease on MRI was performed at baseline, month+3 and month+12 post-IMRT. Potential prognostic factors were analysed for tumour reduction and relapse-free survival, and assessed by log-rank and Cox regression analyses. Results: 32 patients with IDHmutAG of the insular cortex were managed with median follow-up post-IMRT of 67.2 months. Pathology was anaplastic astrocytoma (AAmut) in 20, and anaplastic oligodendroglioma (AOD) in 12 patients. Median pre-IMRT volume on T1 and T2Flair was 24.3cm3 and 52.2cm3. Twenty-seven patients were alive with 5-year relapse-free survival of 80%. There was a median 67% and 64% reduction from baseline occurring at 3 months post-IMRT for T1 and T2Flair respectively; and subsequent median 78% and 73% at 12 months. At 12 months AOD patients had median 83% T1 volume reduction compared to 63% in AAmut (p<0.01). There was no difference on T2Flair volume (p=0.64). No other pathological factors influenced volume reduction at 12 months. No factors were associated with relapse-free survival including baseline T1 (p=0.52) and T2Flair (p=0.93) volume.Conclusion:IMRT provides large tumour volume reduction in IDHmutAG of the insular cortex with no significant negative impact of residual disease volume on relapse-free survival.
Volumetric modulated arc therapy (VMAT) in breast radiotherapy has seen limited uptake in routine care. Barriers to adoption include concerns regarding toxicity, dosimetry and low dose wash. There is a lack of modern data to address these concerns. Therefore, the aim of this study is to report on real-world outcomes from a single-class solution implementation of VMAT planned with knowledge-based planning (KBP). A retrospective review of all breast cancer patients undergoing definitive radiotherapy at Royal North Shore Hospital (Sydney, Australia) from June 2020 to June 2023 inclusive was undertaken. All patients were treated with a VMAT technique and planned with KBP. Prospectively collected dosimetry and toxicity data was collated. We identified 484 patients satisfying the inclusion criteria. Doses to constraints easily met international guidelines. For breast/chest-wall alone patients (n = 349), the median average heart dose was <2 Gy for standard fractionation (SF), <1.05 Gy for hypofractionated (HF) and <0.7 Gy for ultrahypofractionated (UHF) patients. The median average ipsilateral lung dose was <7.7 Gy for SF patients, <5.3 Gy for HF patients and <3.6 Gy for UHF patients. Nearly all patients (99%) achieved at least D95% ≥ 95% of the prescribed dose (TD) to the CTV primary. For acute toxicity, there were no clinician-reported high grade (Grade ≥ 3) toxicities and no pneumonitis recorded. This study demonstrates the technical feasibility, excellent dosimetry, and low clinician-reported acute toxicity of a standardised KBP-VMAT approach within a large, real-world cohort. Our approach easily met constraints set in recent international guidelines and randomised controlled trial protocols. While limited by its retrospective, single-arm nature and lack of long-term toxicity outcomes, this study adds to a growing body of literature on the use and outcomes of modern VMAT in breast radiotherapy.